1.67
-0.04(-2.34%)
Currency In USD
| Previous Close | 1.71 |
| Open | 1.7 |
| Day High | 1.7 |
| Day Low | 1.66 |
| 52-Week High | 4.2 |
| 52-Week Low | 1.12 |
| Volume | 209,450 |
| Average Volume | 245,179 |
| Market Cap | 124.44M |
| PE | -41.75 |
| EPS | -0.04 |
| Moving Average 50 Days | 1.78 |
| Moving Average 200 Days | 2.23 |
| Change | -0.04 |
If you invested $1000 in Inhibikase Therapeutics, Inc. (IKT) since IPO date, it would be worth $28.11 as of September 07, 2025 at a share price of $1.67. Whereas If you bought $1000 worth of Inhibikase Therapeutics, Inc. (IKT) shares 3 years ago, it would be worth $307.55 as of September 07, 2025 at a share price of $1.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
GlobeNewswire Inc.
Aug 19, 2025 12:00 PM GMT
BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
GlobeNewswire Inc.
Apr 14, 2025 12:00 PM GMT
BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arter
Inhibikase Announces Expansion of Senior Leadership Team
GlobeNewswire Inc.
Feb 24, 2025 1:00 PM GMT
--- Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of Directors --- BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE)